Announcements Trials
Browse Landscape

Phase

Phase 3 2

Status

Completed 1Active not recruiting 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 2

Conditions

Carcinoma, Non-Small-Cell Lung 3Melanoma 2Carcinoma, Renal Cell 2Carcinoma, Hepatocellular 2Various Advanced Cancer 1Uveal Melanoma 1Urothelial Cancer 1Stomach Neoplasms 1Microsatellite Unstable Colorectal Cancer 1Mesothelioma 1Colorectal Neoplasms 1Advanced or Metastatic Solid Tumors 1Adenocarcinoma Of Esophagus 1

Interventions

Sunitinib 7Nivolumab 4pembrolizumab 3cabozantinib 2Ipilimumab 2Everolimus 2Axitinib 2ulixertinib 1trastuzumab biosimilar HLX02 1trametinib 1sapanisertib 1sacituzumab govitecan 1relatlimab 1pertuzumab 1palbociclib 1osimertinib 1omipalisib 1lenvatinib 1larotrectinib 1ipatasertib 1erdafitinib 1entrectinib 1defactinib 1dabrafenib 1copanlisib 1capivasertib 1binimetinib 1belzutifan 1avelumab 1adavosertib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Has announcements × Carcinoma, Renal Cell × Ipilimumab × Clear all
NCT02231749 2026-05-27

Nivolumab Combined With Ipilimumab Versus Sunitinib in Previously Untreated Advanced or Metastatic Renal Cell Carcinoma (CheckMate 214)

Bristol-Myers Squibb

Phase 3 Completed
1,096 enrolled 17 charts 1 FDA
Genitourinary

Carcinoma, Renal Cell

NCT03141177 2025-06-06

CheckMate 9ER

Bristol-Myers Squibb

Phase 3 Active not recruiting
701 enrolled 17 charts 1 FDA
Genitourinary

Carcinoma, Renal Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡